Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Materials Select Sector SPDR Fund — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.38 (market cap $5.07B), while Materials Select Sector SPDR Fund trades at $52.73. Which is the better fit depends on your goals.
| ACAD | XLB | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | — |
52-Week High | $29.41 | $53.62 |
52-Week Low | $20.06 | $42.23 |
Enterprise Value | $4.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
XLB trades at $53.14, showing minimal daily movement with a slight decline of 0.08%. Technical indicators signal a bullish trend with strong moving average support and oscillators showing mixed signals. The materials sector ETF benefits from infrastructure spending and AI-related demand, though recent articles suggest the cyclical recovery may be largely priced in. Dividend payments are scheduled for 2026.
The outlook for XLB remains positive due to sector tailwinds from infrastructure and manufacturing trends, though valuation concerns exist after recent gains. Key risks include cyclical sector exposure and potential overvaluation. Analyst sentiment appears cautiously optimistic with technical strength supporting near-term momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
